Core Viewpoint - 泰德医药's stock price increased over 9%, reaching a new high of 40.54 HKD, driven by positive market sentiment ahead of its upcoming board meeting to approve mid-term results [1] Company Summary - 泰德医药 is the third largest global player in the peptide-focused CRDMO market, holding a market share of 1.5% as of 2023, according to Frost & Sullivan [1] - The company offers a full-cycle service from early discovery, preclinical research, clinical development to commercial production [1] - The top two players in the global peptide-focused CRDMO market account for 23.8% of the market share, while the remaining participants are more fragmented, with the third to sixth largest players, including 泰德医药, each holding approximately 1% market share [1] Financial Performance - 泰德医药's revenue for the past few years has shown strong momentum, with figures of 351 million, 337 million, and 442 million CNY [1] - The company's diverse client base and global presence support its growth, with clients spanning over 50 countries [1] - Revenue distribution is as follows: 55% from the United States, 21.4% from mainland China, 7.1% from Japan, and 11% from Europe, indicating a well-diversified market presence that mitigates risks associated with reliance on a single market [1]